ACM
HALO icon

Advent Capital Management’s Halozyme HALO Stock Holding History

Advent Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-75,000
Closed -$953K – 472
2014
Q1 		$953K Buy
+75,000
New +$1.11M 0.01% 387

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Advent Capital Management's HALO Position: Q2 2014 in Review

Advent Capital Management sold out of Halozyme (HALO) in Q2 2014, closing a stake of 75,000 shares — an estimated $953K sold.

Advent Capital Management first reported a position in HALO in Q1 2014 and held it in 1 quarter. The position peaked at $953K in Q1 2014. 128 funds tracked by Wall St. Rank hold HALO as of Q2 2014.

  • Advent Capital Management reported no remaining Halozyme position as of Q2 2014 after selling out during the quarter.
  • Advent Capital Management sold 75,000 Halozyme shares in Q2 2014, an estimated $953K.
  • Advent Capital Management first reported a position in Halozyme in Q1 2014 and held it in 1 quarter.
  • Advent Capital Management's Halozyme position peaked at $953K in Q1 2014.
  • 128 funds tracked by Wall St. Rank held Halozyme as of Q2 2014.

Based on Advent Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.